Infliximab reduces the expression of CD147 on the peripheral CD14+ monocytes of active rheumatoid arthritis patients
10.3760/cma.j.issn.1007-7480.2010.07.007
- VernacularTitle:英夫利西单抗对类风湿关节炎患者外周血单核细胞CD147表达的影响
- Author:
Baozhao XIE
;
Jianlin HUANG
;
Shiyao WU
;
Shuangyan CAO
;
Qiujing WEI
;
Jieruo GU
- Publication Type:Journal Article
- Keywords:
Arthritis,rheumatoid;
Tumor necrosis factors;
Therapy;
CD147
- From:
Chinese Journal of Rheumatology
2010;14(7):464-467
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of infliximab combination therapy on the expression of CD147 on the peripheral CD14+ monocytes of active rheumatoid arthritis (RA) patients. Methods Thirty active RA patients who were refractory to MTX treatment were randomized into three groups (group A, B, C) with the proportion of 3:1:1. Group A and B received four or three infusions of infliximab (3 mg/kg), group C received four infusions of placebo. All three groups were added to a stable background of MTX. The mean fluorescence intensity (MFI) of CD147 expression on the peripheral CD14+ monocytes of RA patients and normal healthy controls were detected by flow cytometry analysis. Clinical and laboratory parameters were assessed before each infusion. One-way ANOVA, Kruskal-Wallis the MFI of CD147 expression at week 18 (P<0.05). Marked differences were observed between the infliximab + MTX group and the placebo + MTX group on the change of the MFI of CD147 expression from baseline to week 18 (P<0.05).Conclusion CD147 expression on the peripheral CD14+ monocytes of active RA patients is increased, and combination therapy of infliximab and MTX can inhibit the expression.
